3-溴-8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮 | 156073-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并环庚烷吡啶
• 中文名称: 3-溴-8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮
• 英文名称: 3-BROMO-8-CHLORO-5,6-DIHYDRO-11H-BENZO[5,6]-CYCLOHEPTA[1,2-b]PYRIDIN-11-ONE
• 英文别名: 3-bromo-8-chloro-5,6-dihydro-11H-benzo<5,6>cyclohepta<1,2-b>pyridin-11-one；3-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]-Cyclohepta[1,2-b]Pyridin-11-On；3-bromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one；3-bromo-8-chloro-5,6-diydro-11H-benzo[5,6]cyclohepta[1,2-b]oyridin-11-one；6-bromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-one
• CAS: 156073-28-8
• 化学式: C₁₄H₉BrClNO
• 分子量: 322.589
• InChiKey: CSUZZEVXBPNANR-UHFFFAOYSA-N

物化性质

• 沸点：
  475.9±45.0 °C(Predicted)
• 密度：
  1.599±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-溴-8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮 在 N-甲基吗啉 、 sodium tetrahydroborate 、 氯化亚砜 、 硫酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 45.5h， 生成 1-(3-Bromo-8-chloro-6,11-dihydro-5 H-benzo[5,6]-cyclohepta[1,2-b] pyridin-11-yl)-4-[(4-piperidinyl)acetyl]-piperazine
  参考文献：
  名称：

  Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine

  摘要：

  The synthesis of a variety of novel 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin -11-yl)piperazine to explore the SAR of of this series of FPT inhibitors is described. This resulted in the synthesis of the 4- and 3-pyridylacetyl analogues 45a and 50a, respectively, both of which were orally active but were found to be rapidly metabolized in vivo. Identification of the principal metabolites led to the synthesis of a variety of new compounds that would be less readily metabolized, the most interesting of which were the 3- and 4-pyridylacetyl N-oxides 80a and 83a. Novel replacements for the pyridylacetyl moiety were also sought, and this resulted in the discovery of the 4-N-methyl and 4-N-carboxamidopiperidinylacetyl derivatives 135a and 160a, respectively. All of these derivatives exhibited greatly improved pharmacokinetics. The synthesis of the corresponding 3-bromo analogues resulted in the discovery of the 4-pyridylacetyl N-oxides 83b (+/-) and 85b [11S(-)] and the 4-carboxamidopiperidinylacetamido derivative 160b (+/-), all of which exhibited potent FPT inhibition in vitro. All three showed excellent oral bioavailability in vivo in nude mice and cynomolgus monkeys and exhibited excellent antitumor efficacy against a series of tumor cell lines when dosed orally in nude mice.

  DOI：

  10.1021/jm970462w
• 作为产物：
  描述：

  4-(3-溴-8-氯-5,6-二氢-11H-苯并[5,6]环庚[1,2-B]吡啶-11-亚基)哌啶-1-羧酸乙酯 在 ruthenium trichloride 、 sodium periodate 作用下， 以 水 、 乙腈 为溶剂， 反应 1.5h， 以64%的产率得到3-溴-8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮
  参考文献：
  名称：

  (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336):  A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent

  摘要：

  We have previously shown that appropriate modification of the benzocycloheptapyridine tricyclic ring system can provide potent farnesyl protein transferase (FPT) inhibitors with good cellular activity. Our laboratories have also established that incorporation of either pyridinylacetyl N-oxide or 4-N-carboxamidopiperidinylacetyl moieties results in pharmacokinetically stable inhibitors that are orally efficacious in nude mice. We now demonstrate that further elaboration of the tricyclic ring system by introducing a bromine atom at the 7- or the 10-position of the 3-bromo-8-chlorotricyclic ring system provides compounds that have superior potency and selectivity in FPT inhibition. These compounds have good serum levels and half-lives when given orally to rodents and primates. In vitro and in vivo evaluation of a panel of these inhibitors has led to identification of 15 (SCH 66336) as a highly potent (IC50 = 1.9 nM) antitumor agent that is currently undergoing human clinical trials.

  DOI：

  10.1021/jm980462b

文献信息

• Tricyclic amide and urea compounds useful for inhibition of G-protein
  申请人：Schering Corporation

  公开号：US05700806A1

  公开（公告）日：1997-12-23

  Novel compounds of Formula (7.0a), (7.0b) or (7.0c): ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

  揭示了化合物的新颖结构，其化学式为(7.0a)、(7.0b)或(7.0c)：##STR1##。还揭示了一种抑制Ras功能从而抑制细胞异常生长的方法。该方法包括向生物系统施用化合物的化学式(7.0a)、(7.0b)或(7.0c)。具体而言，该方法抑制了哺乳动物（如人类）中细胞的异常生长。
• Tricyclic carbamate compounds useful for inhibition of G-protein
  申请人：Schering Corporation

  公开号：US06075025A1

  公开（公告）日：2000-06-13

  A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 ##STR1## Also disclosed are novel compounds of the formulas: ##STR2## Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

  揭示了一种抑制Ras功能从而抑制细胞生长的方法。该方法包括给予Formula 1.0的化合物。还揭示了以下公式的新化合物：还揭示了制备公式1.1、1.2和1.3的3-取代化合物的方法。进一步揭示了在制备公式1.1、1.2和1.3的3-取代化合物的过程中的新化合物。
• Tricyclic amide and urea compounds useful for inhibition of g-protein
  申请人：Schering Corporation

  公开号：US05719148A1

  公开（公告）日：1998-02-17

  A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

  抑制Ras功能从而抑制细胞异常生长的方法已被披露。该方法包括向生物系统中施用Formula 1.0的化合物：##STR1##。具体来说，该方法抑制了哺乳动物（如人类）中细胞的异常生长。还披露了Formula 5.0、5.1和5.2的新化合物，其中R为--C(R.sup.20)(R.sup.21)(R.sup.46)，以及Formula 5.3、5.3A和5.3B，其中R为--N(R.sup.25)(R.sup.48)。还披露了制备Formula 5.0、5.1、5.2和5.3的3-取代化合物的方法。此外，还披露了在制备Formula 5.0、5.1、5.2和5.3的3-取代化合物过程中的中间体新化合物。
• Synthesis of Isomeric 3-Piperidinyl and 3-Pyrrolidinyl Benzo[5,6]cyclohepta[1,2-b]pyridines: Sulfonamido Derivatives as Inhibitors of Ras Prenylation
  作者：Joseph Kelly、Ronald Wolin、Michael Connolly、Adriano Afonso、Linda James、Paul Kirshmeier、W.Robert Bishop、Andrew T. McPhail

  DOI：10.1016/s0968-0896(98)00026-1

  日期：1998.6

  Blocking farnesylation of oncogenic Ras proteins is a mechanism based therapeutic approach that is of current interest for the development of antitumor agents to treat ras associated tumors. As part of a SAR study on the lead farnesyl protein transferase (FPT) inhibitor I, we report here the synthesis of novel geometric isomers II and III and the FPT inhibition activity of their N-acyl and N-sulfonamido

  阻断致癌性Ras蛋白的法尼基化是一种基于机制的治疗方法，目前对于开发治疗ras相关肿瘤的抗肿瘤药物具有重要意义。作为对法呢基铅蛋白转移酶（FPT）抑制剂I的SAR研究的一部分，我们在这里报告了新型几何异构体II和III的合成及其N-酰基和N-磺酰胺基衍生物15-65的FPT抑制活性。N-酰基衍生物的活性显着低于铅抑制剂I，从而表明I中N-酰基的空间位置对于化合物与FPT的结合至关重要。与I相反，N-磺酰胺基-II系列是非巯基非肽类化合物的新型先导，它们是FPT / GGPT双重抑制剂。根据最近有关N-和K-Ras异戊烯化的报道，
• A Novel Enantioselective Alkylation and Its Application to the Synthesis of an Anticancer Agent
  作者：Shen-Chun Kuo、Frank Chen、Donald Hou、Agnes Kim-Meade、Charles Bernard、Jinchu Liu、Stacy Levy、George G. Wu

  DOI：10.1021/jo034380t

  日期：2003.6.1

  A novel enantioselective alkylation of double benzylic substrates with secondary electrophiles is reported. A simple norephedrine-based chiral ligand was synthesized that gives alkylation product in 95% yield and 95% ee. A unique water effect on the enantioselectivity was unveiled. Good to excellent ee values were obtained with a number of double benzylic substrates and secondary electrophiles. This

  报道了具有仲亲电试剂的双苄基底物的新型对映选择性烷基化。合成了一种简单的基于去氧麻黄碱的手性配体，该烷基化产物的收率为95％，ee为95％。揭示了对对映选择性的独特水效应。使用许多双苄基底物和第二亲电试剂可获得良好至优异的ee值。该新反应已被应用于有希望的抗癌剂的合成。